• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

可能用于治疗新冠肺炎患者的药物。

Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients.

作者信息

Shihab Mehdi Salih, Hamah-Ameen Baram

机构信息

Pharmacy Department, Al- Esraa University College, 10001 Baghdad, Iraq.

Chemistry Department, College of Science, Al-Nahrain University, 10001 Baghdad, Iraq.

出版信息

Russ J Bioorg Chem. 2021;47(4):789-804. doi: 10.1134/S1068162021040130. Epub 2021 Aug 21.

DOI:10.1134/S1068162021040130
PMID:34456540
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8380022/
Abstract

The drug development process for Coronavirus disease (COVID-19) is the research process to create a preventive vaccine or therapeutic prescription drug to relieve the severity of 2019-2020 (COVID-19). In different stages of preclinical or clinical research, several hundred special scientific research centers, research organizations, and health agencies have developed and tried enormous numbers of vaccine candidates and new drugs for COVID-19 disease. In order to identify new therapies against COVID-19, several clinical trials have been in progress worldwide.

摘要

冠状病毒病（COVID-19）的药物研发过程是开发预防性疫苗或治疗性处方药以减轻2019-2020年冠状病毒病（COVID-19）严重程度的研究过程。在临床前或临床研究的不同阶段，数百个专业科研中心、研究组织和卫生机构已经研发并试验了大量针对COVID-19疾病的候选疫苗和新药。为了确定针对COVID-19的新疗法，全球范围内正在进行多项临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/cd13478f7111/11171_2021_8341_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/2a3973dc5611/11171_2021_8341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/213ac8cfed87/11171_2021_8341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/08e8a235a502/11171_2021_8341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/ec97287747f1/11171_2021_8341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/3557d8627d95/11171_2021_8341_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/cd13478f7111/11171_2021_8341_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/2a3973dc5611/11171_2021_8341_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/213ac8cfed87/11171_2021_8341_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/08e8a235a502/11171_2021_8341_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/ec97287747f1/11171_2021_8341_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/3557d8627d95/11171_2021_8341_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f9dc/8380022/cd13478f7111/11171_2021_8341_Fig6_HTML.jpg

相似文献

1
Drugs that Might Be Possibly Used for Treatment of COVID-19 Patients.可能用于治疗新冠肺炎患者的药物。
Russ J Bioorg Chem. 2021;47(4):789-804. doi: 10.1134/S1068162021040130. Epub 2021 Aug 21.
2
The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.新型冠状病毒病患者核酸检测由阴转阳的机制及临床转归和法匹拉韦的疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):488. doi: 10.1186/s13063-020-04430-y.
3
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
4
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
5
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究：研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
6
Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.格拉斯哥早期治疗组法维拉韦（GETAFIX）治疗 COVID-19 早期成人患者：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Nov 19;21(1):935. doi: 10.1186/s13063-020-04891-1.
7
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
8
Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.COVID-19 门诊患者的早期抗病毒治疗（FLARE）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Mar 8;22(1):193. doi: 10.1186/s13063-021-05139-2.
9
Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.抗 SARS-CoV-2 感染的 FDA 批准药物在雪貂中的抗病毒疗效。
mBio. 2020 May 22;11(3):e01114-20. doi: 10.1128/mBio.01114-20.
10
A Mini Review on Emerging Targets and Approaches for the Synthesis of Anti-viral Compounds: In Perspective to COVID-19.
Mini Rev Med Chem. 2021;21(10):1173-1181. doi: 10.2174/1389557521666210104165733.

本文引用的文献

1
Favipiravir in Therapy of Viral Infections.法匹拉韦在病毒感染治疗中的应用
J Clin Med. 2021 Jan 13;10(2):273. doi: 10.3390/jcm10020273.
2
Potential Anti-SARS-CoV-2 Therapeutics That Target the Post-Entry Stages of the Viral Life Cycle: A Comprehensive Review.潜在的针对病毒生命周期进入后阶段的抗 SARS-CoV-2 治疗药物：全面综述。
Viruses. 2020 Sep 26;12(10):1092. doi: 10.3390/v12101092.
3
Favipiravir: A new and emerging antiviral option in COVID-19.法匹拉韦：COVID-19 中一种新兴的抗病毒新选择。
Med J Armed Forces India. 2020 Oct;76(4):370-376. doi: 10.1016/j.mjafi.2020.08.004. Epub 2020 Sep 2.
4
Correction for Khan et al., "Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: Biology and Therapeutic Options".对汗等人的《一种新型冠状病毒——严重急性呼吸综合征冠状病毒2的出现：生物学与治疗选择》的勘误
J Clin Microbiol. 2020 Jul 23;58(8). doi: 10.1128/JCM.01297-20.
5
SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.严重急性呼吸综合征冠状病毒2：重新利用的药物和新型治疗方法——对化学结构、生物活性和毒理学筛选的见解
J Clin Med. 2020 Jul 2;9(7):2084. doi: 10.3390/jcm9072084.
6
Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.洛匹那韦/利托那韦在新冠病毒病治疗中的作用：当前证据、指南推荐及展望综述
J Clin Med. 2020 Jun 30;9(7):2050. doi: 10.3390/jcm9072050.
7
Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.甲磺酸那法莫司他联合法匹拉韦治疗新型冠状病毒肺炎危重症患者：病例系列
Crit Care. 2020 Jul 3;24(1):392. doi: 10.1186/s13054-020-03078-z.
8
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）：全球大流行及治疗策略。
Int J Antimicrob Agents. 2020 Aug;56(2):106054. doi: 10.1016/j.ijantimicag.2020.106054. Epub 2020 Jun 10.
9
Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19.氯喹和羟氯喹在治疗 COVID-19 中的应用进展。
Postgrad Med. 2020 Sep;132(7):604-613. doi: 10.1080/00325481.2020.1778982. Epub 2020 Jun 21.
10
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).全面分析治疗 SARS-CoV-2 感染的药物：当前 COVID-19 疗法的机制见解（综述）。
Int J Mol Med. 2020 Aug;46(2):467-488. doi: 10.3892/ijmm.2020.4608. Epub 2020 May 18.